BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 1419807)

  • 1. Patterns of development of tachyphylaxis in patients with haemophilia and von Willebrand disease after repeated doses of desmopressin (DDAVP).
    Mannucci PM; Bettega D; Cattaneo M
    Br J Haematol; 1992 Sep; 82(1):87-93. PubMed ID: 1419807
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Response of factor VIII/von Willebrand factor to DDAVP in healthy subjects and patients with haemophilia A and von Willebrand's disease.
    Mannucci PM; Canciani MT; Rota L; Donovan BS
    Br J Haematol; 1981 Feb; 47(2):283-93. PubMed ID: 6781527
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Factor VIII:C increases after desmopressin in a subgroup of patients with autosomal recessive severe von Willebrand disease.
    Castaman G; Lattuada A; Mannucci PM; Rodeghiero F
    Br J Haematol; 1995 Jan; 89(1):147-51. PubMed ID: 7833254
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Response of patients with hemophilia A and von Willebrand disease to desmopressin (DDAVP).
    Santiago-Borrero PJ; Casanova R
    Bol Asoc Med P R; 1990 May; 82(5):207-10. PubMed ID: 2115785
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nasal spray desmopressin (DDAVP) for mild hemophilia A and von Willebrand disease.
    Rose EH; Aledort LM
    Ann Intern Med; 1991 Apr; 114(7):563-8. PubMed ID: 1900403
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Endothelial stimulation by DDAVP in von Willebrand's disease and haemophilia.
    Greer IA; McLaren M; Belch JJ; Lowe GD; Forbes CD
    Haemostasis; 1986; 16(1):15-9. PubMed ID: 3084364
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Response of von Willebrand factor parameters to desmopressin in patients with type 1 and type 2 congenital von Willebrand disease: diagnostic and therapeutic implications.
    Michiels JJ; van de Velde A; van Vliet HH; van der Planken M; Schroyens W; Berneman Z
    Semin Thromb Hemost; 2002 Apr; 28(2):111-32. PubMed ID: 11992235
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Desmopressin (DDAVP) for treatment of disorders of hemostasis.
    Mannucci PM
    Prog Hemost Thromb; 1986; 8():19-45. PubMed ID: 3104987
    [TBL] [Abstract][Full Text] [Related]  

  • 9. DDAVP: a useful alternative to blood components in moderate hemophilia A and von Willebrand disease.
    Warrier AI; Lusher JM
    J Pediatr; 1983 Feb; 102(2):228-33. PubMed ID: 6401806
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Factor VII and fibrinolytic response to deamino-8-D-argenine vasopressin in normal subjects and dissociate response in some patients with haemophilia and von Willebrand's disease.
    Ludlam CA; Peake IR; Allen N; Davies BL; Furlong RA; Bloom AL
    Br J Haematol; 1980 Jul; 45(3):499-511. PubMed ID: 6775673
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II prospective open-label trial of recombinant interleukin-11 in desmopressin-unresponsive von Willebrand disease and mild or moderate haemophilia A.
    Ragni MV; Novelli EM; Murshed A; Merricks EP; Kloos MT; Nichols TC
    Thromb Haemost; 2013 Feb; 109(2):248-54. PubMed ID: 23238591
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intraleucocyte platelet-activating factor levels in desmopressin-treated patients with haemophilia A and von Willebrand disease.
    Kavakli K; Hüseyinov A; Coker I; Aydinok Y; Nisli G
    Haemophilia; 2001 Sep; 7(5):482-9. PubMed ID: 11554936
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intravenous DDAVP and factor VIII-von Willebrand factor concentrate for the treatment and prophylaxis of bleedings in patients With von Willebrand disease type 1, 2 and 3.
    Michiels JJ; van Vliet HH; Berneman Z; Gadisseur A; van der Planken M; Schroyens W; van der Velden A; Budde U
    Clin Appl Thromb Hemost; 2007 Jan; 13(1):14-34. PubMed ID: 17164493
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patients with severe von Willebrand disease are insensitive to the releasing effect of DDAVP: evidence that the DDAVP-induced increase in plasma factor VIII is not secondary to the increase in plasma von Willebrand factor.
    Cattaneo M; Simoni L; Gringeri A; Mannucci PM
    Br J Haematol; 1994 Feb; 86(2):333-7. PubMed ID: 8199023
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Desmopressin: therapeutic limitations in children and adults with inherited coagulation disorders.
    Nolan B; White B; Smith J; O'Reily C; Fitzpatrick B; Smith OP
    Br J Haematol; 2000 Jun; 109(4):865-9. PubMed ID: 10929043
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of high concentration intranasal and intravenous desmopressin in pediatric patients with mild hemophilia A or mild-to-moderate type 1 von Willebrand disease.
    Gill JC; Ottum M; Schwartz B
    J Pediatr; 2002 May; 140(5):595-9. PubMed ID: 12032528
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hyper-responsiveness to DDAVP for patients with type I von Willebrand's disease and normal intra-platelet von Willebrand factor.
    Rodeghiero F; Castaman G; Di Bona E; Ruggeri M; Lombardi R; Mannucci PM
    Eur J Haematol; 1988 Feb; 40(2):163-7. PubMed ID: 3126081
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Laboratory diagnosis of von Willebrand disease type 1/2E (2A subtype IIE), type 1 Vicenza and mild type 1 caused by mutations in the D3, D4, B1-B3 and C1-C2 domains of the von Willebrand factor gene. Role of von Willebrand factor multimers and the von Willebrand factor propeptide/antigen ratio.
    Gadisseur A; Berneman Z; Schroyens W; Michiels JJ
    Acta Haematol; 2009; 121(2-3):128-38. PubMed ID: 19506359
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intranasal administration of demopressin (DDAVP) for type 1 and type 2A von Willebrand disease.
    Mohri H; Hashimoto Y; Yamazaki E; Kanamori H; Okubo T
    Hematopathol Mol Hematol; 1998; 11(2):109-15. PubMed ID: 9608359
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Desmopressin (DDAVP) responsiveness in children with von Willebrand disease.
    Revel-Vilk S; Schmugge M; Carcao MD; Blanchette P; Rand ML; Blanchette VS
    J Pediatr Hematol Oncol; 2003 Nov; 25(11):874-9. PubMed ID: 14608197
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.